Literature DB >> 20683729

Genomic profiling of cell-free DNA in blood and bone marrow of prostate cancer patients.

Heidi Schwarzenbach1, Felix K-H Chun, Hendrik Isbarn, Hartwig Huland, Klaus Pantel.   

Abstract

PURPOSE: To advance the characterization of tumor-associated cell-free DNA in blood and bone marrow (BM), a rapid profiling method using methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) was established. MS-MLPA detects genetic and epigenetic aberrations of 37 tumor suppressor genes (TSG) in a single reaction and might, therefore, avoid the cumbersome single gene analyses.
METHODS: The validity of MS-MLPA for using cell-free plasma DNA was assessed by analyzing blood and BM samples of 91 patients with prostate cancer. As reference analyses, the methylation patterns of 4 genes (CD44, E-cadherin, CDKN2A and PTEN) chosen from the TSG set of the MS-MLPA kit were investigated in single reactions by sodium bisulfite DNA sequencing.
RESULTS: Copy number changes and aberrant DNA methylation of 37 circulating TSG could be analyzed in BM and blood of 30 and 13 of the 91 patients, respectively, whereas the DNA content in the remaining samples was too low (<50 ng/μl of eluted DNA). The copy number of 28 of the 37 TSG was altered, and most changes were found for APC, CHFR, TP73 and GSTP1 genes in BM plasma. Statistical evaluations showed an association between copy number changes of TP73 and a positive resection margin of the prostate (p = 0.05). Both MS-MLPA and sodium bisulfite sequencing techniques showed that all genes were unmethylated.
CONCLUSIONS: Our results demonstrate the potential and limitation of MS-MLPA for multiplex characterization of TSG in cell-free plasma DNA as a new non-invasive approach to obtain information on the molecular tumor biology of individual cancer patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20683729     DOI: 10.1007/s00432-010-0941-5

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  29 in total

1.  About the possible origin and mechanism of circulating DNA apoptosis and active DNA release.

Authors:  M Stroun; J Lyautey; C Lederrey; A Olson-Sand; P Anker
Journal:  Clin Chim Acta       Date:  2001-11       Impact factor: 3.786

2.  Random mutations, selected mutations: A PIN opens the door to new genetic landscapes.

Authors:  Christoph A Klein
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-20       Impact factor: 11.205

3.  Genetic pattern of prostate cancer progression.

Authors:  T Saric; Z Brkanac; D A Troyer; S S Padalecki; M Sarosdy; K Williams; L Abadesco; R J Leach; P O'Connell
Journal:  Int J Cancer       Date:  1999-04-12       Impact factor: 7.396

Review 4.  Circulating nucleic acids (CNAs) and cancer--a survey.

Authors:  M Fleischhacker; B Schmidt
Journal:  Biochim Biophys Acta       Date:  2006-10-07

5.  Cell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer.

Authors:  Heidi Schwarzenbach; Catherine Alix-Panabières; Imke Müller; Nicolas Letang; Jean-Pierre Vendrell; Xavier Rebillard; Klaus Pantel
Journal:  Clin Cancer Res       Date:  2009-02-01       Impact factor: 12.531

Review 6.  Alterations of tumor suppressor and tumor-related genes in the development and progression of gastric cancer.

Authors:  Gen Tamura
Journal:  World J Gastroenterol       Date:  2006-01-14       Impact factor: 5.742

7.  Microsatellite analysis of allelic imbalance in tumour and blood from patients with prostate cancer.

Authors:  Heidi Schwarzenbach; Felix K-H Chun; Imke Müller; Christoph Seidel; Karoline Urban; Andreas Erbersdobler; Hartwig Huland; Klaus Pantel; Martin G Friedrich
Journal:  BJU Int       Date:  2008-07-01       Impact factor: 5.588

8.  Multimarker circulating DNA assay for assessing blood of prostate cancer patients.

Authors:  Eiji Sunami; Masaru Shinozaki; Celestia S Higano; Robert Wollman; Tanya B Dorff; Steven J Tucker; Steve R Martinez; Ryuich Mizuno; Frederick R Singer; Dave S B Hoon
Journal:  Clin Chem       Date:  2009-01-08       Impact factor: 8.327

9.  Somatic allelic loss at the DCC, APC, nm23-H1 and p53 tumor suppressor gene loci in human prostatic carcinoma.

Authors:  S F Brewster; S Browne; K W Brown
Journal:  J Urol       Date:  1994-04       Impact factor: 7.450

10.  Methylation-specific MLPA (MS-MLPA): simultaneous detection of CpG methylation and copy number changes of up to 40 sequences.

Authors:  Anders O H Nygren; Najim Ameziane; Helena M B Duarte; Raymon N C P Vijzelaar; Quinten Waisfisz; Corine J Hess; Jan P Schouten; Abdellatif Errami
Journal:  Nucleic Acids Res       Date:  2005-08-16       Impact factor: 16.971

View more
  10 in total

Review 1.  APC gene hypermethylation and prostate cancer: a systematic review and meta-analysis.

Authors:  Yang Chen; Jie Li; Xiaoxiang Yu; Shuai Li; Xuerong Zhang; Zengnan Mo; Yanling Hu
Journal:  Eur J Hum Genet       Date:  2013-01-09       Impact factor: 4.246

Review 2.  Regulation of cancer metastasis by cell-free miRNAs.

Authors:  Maša Alečković; Yibin Kang
Journal:  Biochim Biophys Acta       Date:  2014-10-28

3.  DNA methylation in promoter region as biomarkers in prostate cancer.

Authors:  Mihi Yang; Jong Y Park
Journal:  Methods Mol Biol       Date:  2012

4.  Diagnostic utility of MS-MLPA in DNA methylation profiling of adenocarcinomas and neuroendocrine carcinomas of the colon-rectum.

Authors:  Daniela Furlan; Nora Sahnane; Mara Mazzoni; Roberta Pastorino; Ileana Carnevali; Michele Stefanoli; Andrea Ferretti; Anna Maria Chiaravalli; Stefano La Rosa; Carlo Capella
Journal:  Virchows Arch       Date:  2012-12-09       Impact factor: 4.064

5.  Copy number variations of circulating, cell-free DNA in urothelial carcinoma of the bladder patients treated with radical cystectomy: a prospective study.

Authors:  Armin Soave; Felix K-H Chun; Timo Hillebrand; Michael Rink; Lars Weisbach; Bettina Steinbach; Margit Fisch; Klaus Pantel; Heidi Schwarzenbach
Journal:  Oncotarget       Date:  2017-05-07

6.  Meta-analysis of CDKN2A methylation to find its role in prostate cancer development and progression, and also to find the effect of CDKN2A expression on disease-free survival (PRISMA).

Authors:  Zipei Cao; Lijuan Wei; Weizhi Zhu; Xuping Yao
Journal:  Medicine (Baltimore)       Date:  2018-03       Impact factor: 1.889

7.  Copy number variations in primary tumor, serum and lymph node metastasis of bladder cancer patients treated with radical cystectomy.

Authors:  Armin Soave; Lan Kluwe; Hang Yu; Michael Rink; Philipp Gild; Malte W Vetterlein; Philipp Marks; Guido Sauter; Margit Fisch; Christian P Meyer; Tim Ludwig; Roland Dahlem; Sarah Minner; Klaus Pantel; Bettina Steinbach; Heidi Schwarzenbach
Journal:  Sci Rep       Date:  2020-12-09       Impact factor: 4.379

8.  Aberrantly hypermethylated Homeobox A2 derepresses metalloproteinase-9 through TBP and promotes invasion in Nasopharyngeal carcinoma.

Authors:  Hsin-Pai Li; Chen-Ching Peng; I-Che Chung; Mei-Yuan Huang; Shao-Tung Huang; Chia-Chun Chen; Kai-Ping Chang; Cheng-Lung Hsu; Yu-Sun Chang
Journal:  Oncotarget       Date:  2013-11

9.  Multiplexed methylation profiles of tumor suppressor genes and clinical outcome in oligodendroglial tumors.

Authors:  Lu-Ting Kuo; Hsueh-Yi Lu; Chien-Chang Lee; Jui-Chang Tsai; Hong-Shiee Lai; Ham-Min Tseng; Meng-Fai Kuo; Yong-Kwang Tu
Journal:  Cancer Med       Date:  2016-07-01       Impact factor: 4.452

10.  Cell-free DNA release under psychosocial and physical stress conditions.

Authors:  E M Hummel; E Hessas; S Müller; T Beiter; M Fisch; A Eibl; O T Wolf; B Giebel; P Platen; R Kumsta; D A Moser
Journal:  Transl Psychiatry       Date:  2018-10-29       Impact factor: 6.222

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.